The characteristic multipolar morphology of the aidB overexpressi

The characteristic multipolar morphology of the aidB overexpression strain suggests that AidB

could (indirectly) play a role in BAY 73-4506 in vivo Growth or cell division of B. abortus. Methods Strains, plasmids and cell growth All Brucella strains used in this study (Table 1) were derived from B. abortus 544 NalR (a spontaneous nalidixic acid-resistant mutant of B. abortus 544 strain), and were routinely cultivated in rich medium 2YT (1% yeast extract, 1.5% tryptone and 0.5% NaCl, with 1.5% agar for solid medium). E. coli strains DH10B (Invitrogen Life-Technologies) and S17-1 [26] were cultivated in LB broth (0.5% yeast extract, 1% tryptone, 0.5% NaCl) with streptomycin. Antibiotics were used at the following concentrations GSK1210151A nmr when appropriate: nalidixic acid, 25 μg/ml; kanamycin, 20 μg/ml; chloramphenicol, 20 μg/ml. Plasmids were mobilized from E. coli strain S17-1 into B. abortus as previously described [27]. Growth curves were monitored using a Bioscreen system (Thermo

Fisher, ref. 110001-536), allowing continuous monitoring for growth curves in a multiwell format. B. abortus liquid cultures in 2YT medium with the appropriate antibiotic were centrifuged, washed once with PBS and diluted {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| to an OD600 of 0.1 in 2YT (or tryptic soy broth) to start the culture in the Bioscreen system. Each culture (200 μl per well) was performed at 37°C. Control of the B. abortus strain used for the localization screen The fact that the XDB1155 strain is viable and does not present any apparent morphological defects or growth delay suggests that the CFP fusion at the C-terminal of PdhS is not affecting PdhS essential functions. Control immunoblots with anti-GFP antibodies revealed that this fusion protein was stable (data not shown). Observation using fluorescence microscopy showed that PdhS-CFP accumulated Diflunisal at one pole in more than 90% of the cells as previously described [17]. Molecular techniques DNA manipulations were performed according to standard techniques [28]. All plasmids used in this study (Table 1) were constructed by the Gateway™

technique (Invitrogen). To construct an aidB disruption mutant strain, a central 380-bp portion of the aidB CDS was amplified by PCR using AcoA and AcoB primers, and was subcloned into at the EcoRV site of pSKoriTkan vector [29]. The recombinant plasmid was transformed into the E. coli strain S17-1 and introduced into B. abortus 544 NalR strain by mating. Clones in which the plasmid integrated in the genome were selected by growing the bacteria in the presence of kanamycin, and were checked by PCR using AcoDHP1 and pGEM-T-aval primers. Since B. abortus and B. melitensis are nearly identical at the genomic level, entry clones were recovered from the B. melitensis ORFeome version 1.1 [15]. LR recombination cloning procedure was performed as recommended by the manufacturer (Invitrogen Life-Technologies). The sequences of primers are available in Table 2.

Comments are closed.